Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 421: A patient requires immediate relief from an acute asthma attack. Which route of administration would provide the fastest effect?

A. Inhalation (Correct Answer)
B. Oral
C. Subcutaneous
D. Intravenous

Explanation: ***Inhalation*** - **Inhalation** delivers medication directly to the **airways**, the site of action for asthma, allowing for rapid absorption and immediate local bronchodilation. - This route provides **targeted drug delivery** to bronchial smooth muscle, achieving therapeutic effect within **1-5 minutes** for acute asthma relief. - Bypasses first-pass metabolism and requires **lower doses** due to direct delivery to the target organ. - **First-line treatment** for acute asthma attacks in clinical practice. *Oral* - **Oral administration** involves absorption from the gastrointestinal tract, which is a slower process, with onset typically taking **30-60 minutes**. - Medications taken orally undergo **first-pass metabolism** in the liver, reducing bioavailability and delaying therapeutic effect. - Not suitable for **acute** asthma management due to delayed onset. *Subcutaneous* - **Subcutaneous injections** are absorbed more slowly than intravenous or inhaled routes, with onset in **15-30 minutes**. - The drug must diffuse from subcutaneous tissue into the bloodstream before reaching the lungs. - May be used for severe asthma (e.g., subcutaneous epinephrine) but **not preferred** over inhalation for typical acute attacks. *Intravenous* - While **intravenous administration** provides immediate systemic delivery with rapid onset, it is **not the first choice** for acute asthma. - Reserved for **severe, life-threatening asthma** unresponsive to inhaled therapy. - Requires IV access, medical supervision, and carries higher risk of systemic side effects. - For acute asthma relief, **inhaled bronchodilators act faster at the target site** despite IV having faster systemic absorption.

Question 422: A patient with a severe infection is given a drug with a half-life of 8 hours. How long will it take for the drug's concentration to decrease to 25% of its original value?

A. 8 hours
B. 16 hours (Correct Answer)
C. 24 hours
D. 32 hours

Explanation: ***16 hours (Correct)*** - After one **half-life** (8 hours), the drug concentration will be 50% of the original value. - After two half-lives (8 hours + 8 hours = **16 hours**), the drug concentration will be 25% of the original value (50% of 50%). - This follows the exponential decay formula: remaining concentration = (1/2)^n, where n is the number of half-lives. *8 hours (Incorrect)* - This represents only one half-life, at which point the drug's concentration would be reduced to 50%, not 25%, of its original value. - The question asks for the time to reach 25% concentration, which requires an additional half-life. *24 hours (Incorrect)* - This duration represents three half-lives (8 hours × 3). - After three half-lives, the drug concentration would be 12.5% of its original value (50% → 25% → 12.5%). *32 hours (Incorrect)* - This duration represents four half-lives (8 hours × 4). - After four half-lives, the drug concentration would be 6.25% of its original value (12.5% → 6.25%).

Question 423: Comparing cisplatin and carboplatin, which factor primarily accounts for the difference in nephrotoxicity between these two chemotherapeutic agents?

A. Different rates of renal clearance (Correct Answer)
B. Variability in DNA adduct formation
C. Difference in protein binding
D. Dose-dependent cellular uptake

Explanation: ***Different rates of renal clearance*** - **Cisplatin** is largely cleared by **glomerular filtration** and **tubular secretion**, leading to higher concentrations in the renal tubules and increased nephrotoxicity. - **Carboplatin** is primarily cleared by **glomerular filtration** without significant tubular secretion, resulting in lower renal exposure and reduced nephrotoxicity. *Variability in DNA adduct formation* - While both drugs form DNA adducts to exert their therapeutic effect, the specific differences in adduct formation do not primarily explain their differential nephrotoxicity. - The mechanism of nephrotoxicity is more related to the drugs' delivery and concentration in renal cells rather than the inherent nature of their DNA-damaging activity. *Difference in protein binding* - Both cisplatin and carboplatin bind to plasma proteins, but this factor alone does not account for the significant difference in their nephrotoxic profiles. - Protein binding can influence drug distribution and elimination, but the **intrinsic renal handling** mechanisms are more critical for specific organ toxicity. *Dose-dependent cellular uptake* - Both drugs exhibit dose-dependent cellular uptake in target cancer cells, which is crucial for efficacy. - However, the **differential nephrotoxicity** is more closely tied to their **pharmacokinetics** within the kidney itself (e.g., clearance rates) rather than just general cellular uptake.

Question 424: What is the formula for calculating the therapeutic index (TI) of a drug?

A. LD50/ED50 (Correct Answer)
B. EC50/IC50
C. IC50/EC50
D. ED50/LD50

Explanation: ***LD50/ED50*** - The **therapeutic index (TI)** is calculated as the ratio of the **lethal dose for 50% of the population (LD50)** to the **effective dose for 50% of the population (ED50)**. - A higher TI indicates a wider margin of safety, meaning a larger dose is required to produce toxic effects compared to the dose producing therapeutic effects. *EC50/IC50* - This ratio compares the **half maximal effective concentration (EC50)** to the **half maximal inhibitory concentration (IC50)**. - While these terms are important in pharmacology for understanding drug potency and inhibition, they do not directly represent the therapeutic index. *IC50/EC50* - This is the inverse of the previous option, comparing IC50 to EC50. - This ratio is not used for calculating the **therapeutic index**; it might be relevant for understanding the balance between a drug's desired effect and its ability to inhibit a specific process. *ED50/LD50* - This formula represents the inverse of the **therapeutic index**. - A low value of this ratio would indicate a safer drug, but the standard calculation for TI uses LD50 in the numerator to reflect the margin of safety.

Question 425: Which of the following statements is most accurate regarding why fentanyl is preferred over morphine for acute pain management in emergency settings?

A. Morphine has a longer duration of action than fentanyl.
B. Fentanyl is more suitable for acute pain management due to its rapid onset. (Correct Answer)
C. Fentanyl has lower lipid solubility than morphine.
D. Morphine is completely ineffective for acute pain management.

Explanation: ***Fentanyl is more suitable for acute pain management due to its rapid onset.*** - **Fentanyl's high lipid solubility** allows it to cross the blood-brain barrier quickly, leading to a **rapid onset of action**, typically within minutes when administered intravenously. - This rapid onset is crucial in **emergency settings** where immediate pain relief is paramount, allowing for quicker patient comfort and procedural interventions. *Morphine has a longer duration of action than fentanyl.* - Fentanyl generally has a **shorter duration of action** (30-60 minutes intravenously) compared to morphine (2-4 hours intravenously). - While this might necessitate more frequent dosing, the shorter duration can be advantageous for titrating pain relief and managing potential side effects in acute settings. *Fentanyl has lower lipid solubility than morphine.* - Fentanyl has **significantly higher lipid solubility** than morphine, which is why it readily crosses the blood-brain barrier. - This high lipid solubility contributes to its **rapid onset of action** and ability to bind to opioid receptors in the CNS. *Morphine is completely ineffective for acute pain management.* - Morphine is a highly effective opioid narcotic and is widely used for **acute pain management**. - However, its **slower onset of action** compared to fentanyl makes fentanyl often preferred in situations requiring immediate pain relief.

Question 426: Which route of administration provides the fastest onset of action for medications?

A. Intravenous (Correct Answer)
B. Oral
C. Intramuscular
D. Subcutaneous

Explanation: ***Intravenous*** - **Intravenous (IV)** administration directly introduces the medication into the bloodstream, bypassing **absorption barriers**. - This route ensures **100% bioavailability** and the most rapid distribution to target tissues, leading to the fastest onset of action. *Oral* - Oral medications must undergo **absorption** from the gastrointestinal tract and first-pass metabolism in the **liver** before reaching systemic circulation. - This process significantly **delays** the onset of action compared to IV administration. *Intramuscular* - Intramuscular (IM) injections deliver medication into muscle tissue, which is relatively **vascular**, allowing for faster absorption than oral or subcutaneous routes. - However, absorption is still dependent on **muscle blood flow** and drug properties, making it slower than direct IV administration. *Subcutaneous* - Subcutaneous (SC) injections deliver medication into the **fatty tissue** layer beneath the skin. - Absorption from this site is generally **slower** and more sustained compared to IM or IV due to poorer vascularity.

Question 427: In a drug exhibiting first-order kinetics, how would an increase in dose affect the time required to reach the steady-state concentration?

A. It would not change (Correct Answer)
B. It would decrease
C. It would increase
D. It would double

Explanation: ***It would not change*** - For drugs following **first-order kinetics**, the time required to reach steady-state concentration is determined solely by the **half-life (t½)** of the drug, which is independent of the dose. - Steady-state is generally achieved after approximately **4 to 5 half-lives**, regardless of the administered dose size, provided the dosing interval remains constant. *It would decrease* - An increase in dose does not shorten the time to reach steady state for a first-order drug, as the **elimination rate** is proportional to the plasma concentration. - The drug still needs to undergo the same number of half-lives to accumulate to a steady level. *It would increase* - Increasing the dose does not prolong the time to reach steady state for a drug exhibiting first-order kinetics. - The **kinetics of elimination** remain proportional to the amount of drug in the body, meaning a larger dose will be eliminated proportionally faster, maintaining the same half-life. *It would double* - The time to reach steady state is a function of the drug's elimination half-life, not the magnitude of the dose. - Doubling the dose will **double the steady-state concentration**, but not the time it takes to achieve that concentration.

Question 428: Which of the following drugs is LEAST likely to be delivered via a liposome drug delivery system?

A. Amphotericin B
B. Vincristine
C. Amikacin
D. Hyoscine (Correct Answer)

Explanation: ***Hyoscine*** - **Hyoscine** (scopolamine) is a **small, lipid-soluble anticholinergic molecule** that readily crosses cell membranes and the blood-brain barrier due to its high **lipophilicity**. - Its excellent **oral and transdermal bioavailability** and ability to reach target tissues without assistance make liposomal encapsulation unnecessary and clinically redundant. - Unlike the other drugs listed, hyoscine does **not suffer from dose-limiting toxicity** that would benefit from targeted delivery. *Amphotericin B* - **Amphotericin B** is a potent **antifungal agent** with severe dose-limiting **nephrotoxicity** and infusion-related reactions. - **Liposomal formulations (AmBisome®)** are FDA-approved and widely used to significantly **reduce nephrotoxicity** while maintaining antifungal efficacy. - The liposomal delivery alters tissue distribution, reducing kidney exposure while enhancing accumulation in target tissues. *Vincristine* - **Vincristine** is a **vinca alkaloid chemotherapy agent** with dose-limiting **neurotoxicity** and poor tumor penetration. - **Liposomal vincristine (Marqibo®)** is FDA-approved and provides **prolonged circulation time**, enhanced tumor delivery, and reduced neurotoxicity. - The encapsulation improves the therapeutic index by increasing drug concentration at tumor sites. *Amikacin* - **Amikacin** is an **aminoglycoside antibiotic** with significant **nephrotoxicity and ototoxicity** that limit systemic dosing. - **Liposomal amikacin (Arikayce®)** is FDA-approved for mycobacterial lung infections, allowing **targeted pulmonary delivery** with reduced systemic exposure. - The formulation enables higher local drug concentrations with improved safety profile.

Question 429: Which of the following drugs is not an inhibitor of P-glycoprotein?

A. Verapamil
B. Quinidine
C. Phenobarbitone (Correct Answer)
D. Erythromycin

Explanation: ***Phenobarbitone*** - **Phenobarbitone** is primarily known as an **inducer** of various metabolic enzymes, including CYP450 enzymes and **P-glycoprotein itself**. - Unlike the other options, it **increases P-glycoprotein expression** (upregulation) rather than inhibiting its function. - This induction leads to enhanced drug efflux and reduced bioavailability of P-gp substrate drugs, which is the opposite effect of P-gp inhibitors [1]. *Quinidine* - **Quinidine** is a well-known and potent **inhibitor of P-glycoprotein**, often used as a reference compound in studies of P-gp modulation. - It can significantly increase the bioavailability and reduce the elimination of P-gp substrate drugs by blocking the efflux pump. *Verapamil* - **Verapamil** is a potent **calcium channel blocker** and also a significant **inhibitor of P-glycoprotein** [2]. - Its P-gp inhibitory activity contributes to clinical drug interactions by increasing the systemic exposure of co-administered P-gp substrate drugs. *Erythromycin* - **Erythromycin**, a macrolide antibiotic, is a known **inhibitor of P-glycoprotein** [3]. - This inhibition can lead to increased concentrations of co-administered P-gp substrates, contributing to potential drug toxicities.

Question 430: Which of the following drugs has the highest nephrotoxic potential and requires the most careful monitoring in patients with renal failure?

A. Gentamicin (Correct Answer)
B. Ciprofloxacin
C. Vancomycin
D. Ampicillin

Explanation: ***Gentamicin*** - Gentamicin is an **aminoglycoside antibiotic** with the **highest nephrotoxic potential** among the given options, particularly with prolonged use or in patients with pre-existing renal impairment. - Causes **direct tubular toxicity** with an incidence of 5-25%, making it the classic example of drug-induced nephrotoxicity. - Its **narrow therapeutic index** necessitates **careful dose adjustments** based on renal function and **mandatory therapeutic drug monitoring** (peak and trough levels) to prevent accumulation and kidney damage. - Requires the **most intensive monitoring** with serum creatinine, eGFR, and drug levels in renal failure patients. *Vancomycin* - Vancomycin is a **glycopeptide antibiotic** with significant nephrotoxic potential, especially at higher doses (targeting troughs >15-20 mg/L) or in combination with other nephrotoxic agents. - Modern evidence shows nephrotoxicity rates of 5-35% with current dosing regimens, higher than historically recognized. - While vancomycin requires **careful monitoring** (especially trough levels) in renal impairment, aminoglycosides like gentamicin are traditionally considered to have **higher intrinsic nephrotoxic potential** with more predictable dose-dependent tubular damage. *Ciprofloxacin* - Ciprofloxacin, a **fluoroquinolone**, has a **much lower risk of nephrotoxicity** compared to aminoglycosides or vancomycin. - Rare cases of **acute interstitial nephritis** or **crystalluria** can occur, but direct tubular toxicity is uncommon. - While dose adjustment is needed in severe renal impairment, it does not require intensive therapeutic drug monitoring for nephrotoxicity. *Ampicillin* - Ampicillin is a **beta-lactam antibiotic** with the **lowest nephrotoxic potential** among the given options. - Renal impairment can lead to drug accumulation causing CNS toxicity (seizures) but rarely causes direct kidney damage. - Dose adjustments are needed in significant renal failure, but therapeutic drug monitoring is generally not required.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free